FUJIFILM Diosynth Biotechnologies is constructing a $3.2 billion pharmaceutical campus in Holly Springs, N.C. Integrating sophisticated automation technologies, the multi-building development will enable large-scale cell culture manufacturing for the creation of bulk drug substances. Ground was broken in October of 2021 on the first phase, a $2 billion production center slated for completion in early 2025. A subsequent investment of $1.2 billion will establish an additional 425,000-sf plant that will begin operations in 2028. Each phase of construction will initially accommodate eight 20,000-liter bioreactors.
Providing lab, warehouse, and office space, the highly efficient complex will be powered by clean energy. Innovative systems for waste disposal and recycling will advance the company's ambitious sustainability goals. Upon completion, the 1.3 million-sf project will be one of the largest end-to-end cell culture CDMO facilities in the world.
